| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| Targets |
Ki67 PI3Kα 3.72 nM (IC50) PI3Kβ 36.29 nM (IC50) PI3Kδ 1.22 nM (IC50) PI3Kγ 17.09 nM (IC50) PI3K
|
|---|---|
| ln Vitro |
KTC1101 (0.1-50000 nM, 48 h) induced cell cycle arrest at the G1 phase in all tested cell lines (PC3, TMD8, HSC2, HSC4 and CAL33 cells) in a dose-dependent manner and had antiproliferative activity with IC50 ranging from 20 nM to 130 nM, but had no significant pro-apoptotic effect [1]. KTC1101 (0.1-1000 nM, 1 h) showed significant inhibitory activity against all PI3K isoforms in the Adapta kinase assay. The IC50 values of KTC1101 for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ were 3.72 nM, 36.29 nM, 1.22 nM and 17.09 nM, respectively [1]. KTC1101 (0-125 nM, 48 h) showed effective inhibition of the PI3K signaling pathway in WB experiments, with reduced phosphorylation of PI3K downstream effectors AKT and mTOR [1].
|
| ln Vivo |
KTC1101 (0-125 mg/kg orally daily for 14 days) can arrest tumor growth in mice bearing human tumor xenografts, with no signs of recurrence [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: 39 human tumor cell lines, PC3, TMD8, HSC2, HSC4, CAL33 cells, etc. Concentration: 0.1, 1, 10, 100, 1000, 25000, 50000 nM Incubation Duration: 48 h Experimental Results: Exhibited an average GI50 value of 23.4 nM across all cell lines tested, significantly lower than ZSTK474 (HY-50847) (320 nM) and Copanlisib (HY-15346) (134 nM). Western Blot Analysis[1] Cell Types: PC3 cells, TMD8 Tested Concentrations: 0, 5, 25, 125 nM Incubation Duration: 48 h Experimental Results: Showed better inhibitory performance in TMD8 cells compared with ZSTK474 (HY-50847) and Copanlisib (HY-15346). |
| References |
| Molecular Formula |
C21H26F2N8O3
|
|---|---|
| Molecular Weight |
476.48
|
| CAS # |
2764833-47-6
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0987 mL | 10.4936 mL | 20.9872 mL | |
| 5 mM | 0.4197 mL | 2.0987 mL | 4.1974 mL | |
| 10 mM | 0.2099 mL | 1.0494 mL | 2.0987 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
